Keybanc Upgrades Maravai Lifesciences to Overweight, Sets $11.00 Target
The new $11.00 target sits above the $8.00 high among the two firms that rated the stock in the past year.
Maravai Lifesciences MRVI
Maravai Lifesciences Holdings, Inc. · Nasdaq · Pharmaceutical Preparations
$7.68-0.26%close on Nov. 12, 2026 · volume 2.5M · Yahoo Finance
Price, last 58 sessions
Our coverage
Insider buying and selling
No open-market insider buying or selling in the Form 4s filed since July 24, 2026.
Recent SEC filings
All 14 →Financial statements and exhibits
AI summary, unreviewedMaravai LifeSciences Q3 2026 revenue rises 10.1% to $45.9 million and full-year revenue and adjusted EBITDA guidance is raised